A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)
Status:
Not yet recruiting
Trial end date:
2022-11-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of N-hydroxycytidine (NHC)
following a single oral dose of molnupiravir in participants 18 to 75 years (inclusive) with
moderate hepatic impairment and healthy matched controls.